13 out of a total of 50 participating companies were selected by the jury. Apeiron was awarded the maximum amount possible. The non-repayable grant has a total volume of up to EUR 510.000,- for further development of Apeiron’s APN201 project.

APEIRON Biologics AG (Apeiron) today announced that a clinical trial has started with the agent superoxide dismutase (project APN201) to investigate its potential for prevention of radiation dermatitis in breast cancer patients. Press release Presseaussendung

Evotec AG and Apeiron Biologics AG today announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy. Press release Presseaussendung

APEIRON Biologics AG and the Children’s Oncology Group today announced to collaborate in a phase II study with Apeiron’s APN301 in pediatric neuroblastoma patients.Neuroblastoma can be one of the most difficult to treat childhood cancers with about 650 to 750 children diagnosed each year in the U.S. and the E.U., respectively. Press release Presseaussendung

APEIRON Biologics AG (Apeiron) today announced the signing of agreements with the Children’s Cancer Research Institute, Vienna (CCRI) and the European Neuroblastoma Research Network (SIOPEN) that grant Apeiron the rights to further develop and commercialize the monoclonal antibody ch14.18 together with these groups. This antibody presently is being investigated by CCRI and SIOPEN in a…

APEIRON Biologics AG announced that it has entered into an exclusive option to license from the Cleveland Clinic a number of novel compounds. These compounds are currently in development at Cleveland Clinic as drug candidates for treatment of various cancers, designed to fight cancer based on stimulation of the immune system. Press release Presseaussendung

APEIRON Biologics AG (Apeiron) today announced the signing of an agreement that will grant Apeiron the rights to further develop and commercialize the investigational immunocytokine hu14.18-IL2 which has recently shown preliminary activity in a subset of children suffering from neuroblastoma in a Phase II clinical study. Press release Presseaussendung

APEIRON Biologics AG (Apeiron) today announced that Patrick Burgermeister, a seasoned venture capital and pharma manager will play a leading role in the company’s business development activities. He will be engaged in identification and evaluation of new projects, in-licensing/out-licensing activities, portfolio assessment and sourcing new financing opportunities. Press release Presseaussendung